Phase II trial of retroperitoneal lymph node dissection as first-line treatment for testicular seminoma with isolated retroperitoneal disease (1-2cm)

Study Overview

The purpose of this study is to evaluate the safety and effectiveness of Retroperitoneal Lymph Node Dissection (RPLND) as a treatment option for seminoma that has gone to the lymph nodes in the retroperitoneum.

Study Description

This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in the body behind the intestines that is typically the first place that seminoma spreads. RPLND is a surgery that removes lymph nodes in this area to treat testicular seminoma and may experience fewer long-term toxicities, such as a second cancer, cardiovascular disease, metabolic syndrome (pre-diabetes), or lung disease.

Additional Information

Participants will not be paid for their participation.

  • IRB Number: 1601564086 (4T-14-1)
  • Research Study Identifier: TX5915
  • Principal Investigator: Clint Cary, MD

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at or by phone at (888) 264-0005.